13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • TG-1701-101

    Acronym: 

    TG-1701-101

    ACTRN/NCT /ethics: 

    NCT03671590

    Scientific title: 

    Study of TG-1701, an irreversible Bruton's Tyrosine Kinase inhibitor, in patients with B-cell malignancies

    Summary of trial and patient characteristics

    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase I Tumour Stream Non Hodgkin Lymphoma; chronic lymphocytic leukemia
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2018-09-10
    Molecular Target Anticipated End Date 2020-09-01
    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Non Hodgkin Lymphoma; chronic lymphocytic leukemia
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2018-09-10
    Anticipated End Date 2020-09-01

    Trial Summary

    This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a Bruton's Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell malignancies.

    Lay Summary

    Study of TG-1701, an irreversible Bruton's Tyrosine Kinase inhibitor, in patients with B-cell malignancies

    Sponsor / Cooperative group

    TG Therapeutics Inc.

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Recruiting